230 related articles for article (PubMed ID: 31694850)
1. Clot regression effects of rivaroxaban in the treatment of venous thromboembolism in patients with cancer (CRERIT-VTE cancer): study protocol.
Takai S; Nakanishi N; Yokota I; Imai K; Yamada A; Kawasaki T; Okada T; Sawada T; Fujita H; Matoba S
BMJ Open; 2019 Nov; 9(11):e031698. PubMed ID: 31694850
[TBL] [Abstract][Full Text] [Related]
2. Clot-regression effects of rivaroxaban in venous thromboembolism treatment in cancer patients-a prospective interventional study.
Takai S; Nakanishi N; Yokota I; Imai K; Yamada A; Kawasaki T; Kasahara T; Okada T; Sawada T; Matoba S
Sci Rep; 2022 Dec; 12(1):21569. PubMed ID: 36513734
[TBL] [Abstract][Full Text] [Related]
3. A prospective study of Rivaroxaban for central venous catheter associated upper extremity deep vein thrombosis in cancer patients (Catheter 2).
Davies GA; Lazo-Langner A; Gandara E; Rodger M; Tagalakis V; Louzada M; Corpuz R; Kovacs MJ
Thromb Res; 2018 Feb; 162():88-92. PubMed ID: 28416213
[TBL] [Abstract][Full Text] [Related]
4. Direct oral anticoagulants for thromboprophylaxis in ambulatory patients with cancer.
Wang Y; Wang M; Ni Y; Liang Z
Hematology; 2020 Dec; 25(1):63-70. PubMed ID: 31984870
[No Abstract] [Full Text] [Related]
5. Rivaroxaban and Apixaban for Initial Treatment of Acute Venous Thromboembolism of Atypical Location.
Janczak DT; Mimier MK; McBane RD; Kamath PS; Simmons BS; Bott-Kitslaar DM; Lenz CJ; Vargas ER; Hodge DO; Wysokinski WE
Mayo Clin Proc; 2018 Jan; 93(1):40-47. PubMed ID: 29217335
[TBL] [Abstract][Full Text] [Related]
6. Low molecular weight heparin versus rivaroxaban in the treatment of venous thromboembolism in gastrointestinal malignancies.
Choe HK; De Sancho MT; Kim SS; Dai T; Shah MA
Blood Coagul Fibrinolysis; 2018 Mar; 29(2):227-230. PubMed ID: 29389673
[TBL] [Abstract][Full Text] [Related]
7. Rivaroxaban Versus Warfarin for Stroke Prevention and Venous Thromboembolism Treatment in Extreme Obesity and High Body Weight.
Perales IJ; San Agustin K; DeAngelo J; Campbell AM
Ann Pharmacother; 2020 Apr; 54(4):344-350. PubMed ID: 31672028
[No Abstract] [Full Text] [Related]
8. Clinical outcomes and plasma clot permeability and lysability in patients with venous thromboembolism on rivaroxaban: a cohort study.
Frączek P; Krzysztofik M; Stanisz A; Undas A
Pol Arch Intern Med; 2019 Jun; 129(6):377-385. PubMed ID: 31063157
[TBL] [Abstract][Full Text] [Related]
9. Rivaroxaban for Preventing Venous Thromboembolism in High-Risk Ambulatory Patients with Cancer: Rationale and Design of the CASSINI Trial. Rationale and Design of the CASSINI Trial.
Khorana AA; Vadhan-Raj S; Kuderer NM; Wun T; Liebman H; Soff G; Belani C; O'Reilly EM; McBane R; Eikelboom J; Damaraju CV; Beyers K; Dietrich F; Kakkar AK; Riess H; Peixoto RD; Lyman GH
Thromb Haemost; 2017 Nov; 117(11):2135-2145. PubMed ID: 28933799
[TBL] [Abstract][Full Text] [Related]
10. Comparison of an Oral Factor Xa Inhibitor With Low Molecular Weight Heparin in Patients With Cancer With Venous Thromboembolism: Results of a Randomized Trial (SELECT-D).
Young AM; Marshall A; Thirlwall J; Chapman O; Lokare A; Hill C; Hale D; Dunn JA; Lyman GH; Hutchinson C; MacCallum P; Kakkar A; Hobbs FDR; Petrou S; Dale J; Poole CJ; Maraveyas A; Levine M
J Clin Oncol; 2018 Jul; 36(20):2017-2023. PubMed ID: 29746227
[TBL] [Abstract][Full Text] [Related]
11. Effectiveness and safety of rivaroxaban and warfarin in patients with unprovoked venous thromboembolism: a propensity-matched nationwide cohort study.
Larsen TB; Skjøth F; Kjældgaard JN; Lip GYH; Nielsen PB; Søgaard M
Lancet Haematol; 2017 May; 4(5):e237-e244. PubMed ID: 28411120
[TBL] [Abstract][Full Text] [Related]
12. The MARINER trial of rivaroxaban after hospital discharge for medical patients at high risk of VTE. Design, rationale, and clinical implications.
Raskob GE; Spyropoulos AC; Zrubek J; Ageno W; Albers G; Elliott CG; Halperin J; Haskell L; Hiatt WR; Maynard GA; Peters G; Spiro T; Steg PG; Suh EY; Weitz JI
Thromb Haemost; 2016 Jun; 115(6):1240-8. PubMed ID: 26842902
[TBL] [Abstract][Full Text] [Related]
13. Venous thromboembolism therapy with rivaroxaban in daily-care patients: Results from the Dresden NOAC registry.
Keller L; Marten S; Hecker J; Sahin K; Tittl L; Beyer-Westendorf J
Int J Cardiol; 2018 Apr; 257():276-282. PubMed ID: 29506708
[TBL] [Abstract][Full Text] [Related]
14. Effectiveness and safety of rivaroxaban versus warfarin for treatment and prevention of recurrence of venous thromboembolism.
Coleman CI; Bunz TJ; Turpie AGG
Thromb Haemost; 2017 Oct; 117(10):1841-1847. PubMed ID: 28640322
[TBL] [Abstract][Full Text] [Related]
15. Comparison of apixaban to rivaroxaban and enoxaparin in acute cancer-associated venous thromboembolism.
Wysokinski WE; Houghton DE; Casanegra AI; Vlazny DT; Bott-Kitslaar DM; Froehling DA; Hodge DO; Peterson LG; Mcbane RD
Am J Hematol; 2019 Nov; 94(11):1185-1192. PubMed ID: 31378995
[TBL] [Abstract][Full Text] [Related]
16. Cancer-associated thrombosis - treatment and prevention with direct oral factor Xa inhibitors.
Grilusová K; Bolek T; Škorňová I; Staško J; Samoš M; Mokáň M
Klin Onkol; 2021; 34(4):283-290. PubMed ID: 34905929
[TBL] [Abstract][Full Text] [Related]
17. Effectiveness and safety of outpatient rivaroxaban versus warfarin for treatment of venous thromboembolism in patients with a known primary hypercoagulable state.
Coleman CI; Turpie AGG; Bunz TJ; Baker WL; Beyer-Westendorf J
Thromb Res; 2018 Mar; 163():132-137. PubMed ID: 29407625
[TBL] [Abstract][Full Text] [Related]
18. Long-term rivaroxaban for the treatment of acute venous thromboembolism in patients with active cancer in a prospective multicenter trial.
Yhim HY; Choi WI; Kim SH; Nam SH; Kim KH; Mun YC; Oh D; Hwang HG; Lee KW; Song EK; Kwon YS; Bang SM
Korean J Intern Med; 2019 Sep; 34(5):1125-1135. PubMed ID: 29788694
[TBL] [Abstract][Full Text] [Related]
19. Design and rationale for the Japanese Registry of Rivaroxaban Effectiveness & Safety for the Prevention of Recurrence in Patients with Deep Vein Thrombosis and Pulmonary Embolism (J'xactly) study.
Okumura Y; Fukuda I; Nakamura M; Yamada N; Takayama M; Maeda H; Yamashita T; Ikeda T; Mo M; Yamazaki T; Hirayama A;
BMJ Open; 2018 Jun; 8(6):e020286. PubMed ID: 29934383
[TBL] [Abstract][Full Text] [Related]
20. A Retrospective Study on Efficacy and Safety of Rivaroxaban and Dalteparin for Long-Term Treatment of Venous Thromboembolism in Patients with Lung Cancer.
Lee JH; Hyun DG; Choi CM; Lee JC; Kim WS; Oh YM; Lee SD; Lee JS
Respiration; 2019; 98(3):203-211. PubMed ID: 31096241
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
